Jonathan Sporn, Gilgamesh CEO
The Harvard scientist acting as ATAI's treasure trove launches a new psychedelics firm focused on drug 'analogues'
A former Harvard and NIH scientist is returning to the psychedelics field with a new biotech after selling his last effort to the buzzy ATAI …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
